TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15278085
Drug: Nebulized lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized lidocaine (4 mL 10%)
Study: 15278085
Drug: Placebo (nebulized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (nebulized normal saline solution)
Study: 11376302
Drug: Carvedilol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (mean daily dose: 58 ± 1 mg)
Study: 11376302
Drug: Metoprolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (mean daily dose: 162 ± 1 mg)
Study: 9292587
Drug: Zidovudine 100
Normalized name: zidovudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine 100 mg every 4 hours (regimen A)
Study: 9292587
Drug: Zidovudine 300
Normalized name: zidovudine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine 300 mg every 12 hours (regimen B)
Study: 8501929
Drug: Platelet rich
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet rich plasma infusion after heparin reversal
Study: 8501929
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no platelet rich plasma infusion)
Study: 3682857
Drug: Right atrial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right atrial injection of protamine
Study: 3682857
Drug: Left atrial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left atrial injection of protamine
Study: 3682857
Drug: Aortic injection
Normalized name: chloroxylenol / hydrocortisone / pramoxine hydrochloride Otic Solution [Cortic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aortic injection of protamine
Study: 29515279
Drug: Etodolac 400
Normalized name: etodolac 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 400 mg b.i.d
Study: 29515279
Drug: Lornoxicam 8
Normalized name: lornoxicam 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 8 mg b.i.d
Study: 29515279
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 50 mg t.i.d
Study: 23966023
Drug: Oral risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral risperidone (open label) for 4 weeks
Study: 21644418
Drug: Titrated oral
Normalized name: magnesium citrate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated oral misoprostol suspension
Study: 16646026
Drug: Alefacept (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alefacept (15 mg) plus methotrexate (MTX) administered intramuscularly once weekly for 12 weeks
Study: 16646026
Drug: Alefacept (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alefacept (15 mg) plus methotrexate (MTX) in patients with psoriasis involving >= 3% BSA
Study: 2003533
Drug: Erythromycin 333
Normalized name: erythromycin 333 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 333 mg three times daily
Study: 27653448
Drug: AbobotulinumtoxinA solution
Normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: AbobotulinumtoxinA solution for injection 500 U
Study: 25162604
Drug: Fentanyl sublingual
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl sublingual spray (initiated at 100 µg, titrated to effective dose)
Study: 25162604
Drug: Fentanyl sublingual
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl sublingual spray (titration phase)
Study: 23742699
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline (7%) inhaled twice daily for 48 weeks
Study: 23742699
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (0.9%) inhaled twice daily for 48 weeks
Study: 23742699
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of treatment effects
Study: 10728961
Drug: Intravenous ibutilide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ibutilide
Study: 8875098
Drug: Sucralose (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralose (1,000 mg)
Study: 31311577
Drug: I-BiT treatment
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-BiT treatment
Study: 29768152
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg cannabidiol group
Study: 29768152
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg cannabidiol group
Study: 20207340
Drug: Senna (8.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senna (8.6 mg) with docusate (50 mg)
Study: 11050694
Drug: EPI-5 transdermal
Normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPI-5 transdermal patch (5 mg GTN)
Study: 11050694
Drug: EPI-10 transdermal
Normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPI-10 transdermal patch (10 mg GTN)
Study: 11050694
Drug: EPI-15 transdermal
Normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPI-15 transdermal patch (15 mg GTN)
Study: 2941572
Drug: Etodolac 200
Normalized name: etodolac 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 200 mg BID
Study: 2941572
Drug: Etodolac 400
Normalized name: etodolac 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 400 mg BID
Study: 2941572
Drug: Etodolac 600
Normalized name: etodolac 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 600 mg BID
Study: 2941572
Drug: Aspirin 975
Normalized name: aspirin 975 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 975 mg QID
Study: 21999871
Drug: Pioglitazone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15 to 30 mg)
Study: 21999871
Drug: Glimepiride (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (0.5 to 4.0 mg)
Study: 18471513
Drug: Terlipressin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (1 mg intravenously every 6 hours, doubled on day 4 if SCr did not decrease by 30%)
Study: 16199147
Drug: Men with
Normalized name: Peptamen with Prebio Vanilla
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men with COPD, increasing daily number of cigarettes by 10
Study: 10709160
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg oral lansoprazole for 7 days
Study: 9329355
Drug: Human recombinant
Normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human recombinant GH replacement therapy for 6 months (period 1)
Study: 8479462
Drug: Topical tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tretinoin (0.1 percent retinoic acid cream)
Study: 3079487
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy (including diethylstilbestrol, estramustine phosphate, aminoglutethimide, progestational agents, antiandrogens, orchiectomy, LHRH analogues like leuprolide, and combination hormonal therapies)
Study: 27740724
Drug: Dornase treatment
Normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dornase treatment
Study: 27740724
Drug: No dornase
Normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No dornase treatment
Study: 1736695
Drug: Intravenous diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diclofenac
Study: 20673545
Drug: Algorithm-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm-guided treatment
Study: 20673545
Drug: Two different
Normalized name: IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINEPROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY, BIPARATOPIC (TARGETING TWO DIFFERENT NON-OVERLAPP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two different treatment algorithms
Study: 11785838
Drug: Low-dose chemotherapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose chemotherapy with m-BACOD (methotrexate, bleomycin, doxorubicin, vincristine, and dexamethasone)
Study: 11785838
Drug: Standard-dose m-BACOD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose m-BACOD with sargramostim (GM-CSF)
Study: 21723949
Drug: Low-dose S-ketamine
Normalized name: (S)-(-)-ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose S-ketamine
Study: 25241181
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement (formula)
Study: 20728707
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg indomethacin
Study: 16039733
Drug: N-acetylcysteine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine 600 mg orally twice daily for 4 doses
Study: 16039733
Drug: Fenoldopam 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam 0.1 mcg/kg/min intravenously for a minimum of 8 h
Study: 12667380
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (FA, 20 mg per day plus vitamin B(12) 1 mg, intramuscularly, per month for one year, then 20 mg two times a week plus 1 mg per three months for the next year)
Study: 12667380
Drug: Natural beta-carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural beta-carotene (N-betaC, 30 mg per day for first year, then 30 mg two times a week for the next)
Study: 12667380
Drug: Synthetic beta-carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic beta-carotene (S-betaC, administered as in N-betaC)
Study: 8694046
Drug: Misoprostol alone
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol alone (200 micrograms administered vaginally every 12 hours)
Study: 8694046
Drug: Misoprostol with
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol with laminaria (200 micrograms administered vaginally every 12 hours with intracervical placement of laminaria)
Study: 1805818
Drug: rubidazone (zorubicin)
Normalized name: zorubicin
DrugBank: Zorubicin (DB11618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rubidazone (zorubicin) 200 mg/m2/d, days 1 to 4 plus cytarabine (Ara C) 200 mg/m2/d, days 1 to 7 (arm A)
Study: 1805818
Drug: amsacrine (Amsa)
Normalized name: amsacrine
DrugBank: Amsacrine (DB00276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: amsacrine (Amsa) 150 mg/m2/d, days 1 to 4 plus Ara C 200 mg/m2/d, days 1 to 7 (arm B)
Study: 6460974
Drug: mezlocillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: mezlocillin (1 g, intravenously)
Study: 6460974
Drug: ampicillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ampicillin (1 g, intravenously)
Study: 6460974
Drug: mezlocillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: mezlocillin (1 g, intramuscularly)
Study: 6460974
Drug: ampicillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ampicillin (1 g, intramuscularly)
Study: 6460974
Drug: mezlocillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: mezlocillin (1 g, intramuscularly) with probenecid (1 g, orally)
Study: 25115748
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy alone or combined with contingency management
Study: 30183208
Drug: Alprostadil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprostadil (10 μg, once daily) and calcium dobesilate (0.5 g, 3 times daily)
Study: 30183208
Drug: Alprostadil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprostadil (10 μg, once daily)
Study: 26717493
Drug: Lurasidone monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone monotherapy (20-60 or 80-120 mg/day)
Study: 26717493
Drug: Lurasidone adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone adjunctive therapy (20-120 mg/day)
Study: 18446716
Drug: AST-120 (6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST-120 (6.0 g daily for 12 months) plus low-protein diet and RAS blocker therapy (group A)
Study: 14674665
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg twice daily, clarithromycin 250 mg twice daily, metronidazole 500 mg twice daily for 4 days (n = 63)
Study: 14674665
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg twice daily, clarithromycin 250 mg twice daily, metronidazole 500 mg twice daily for 7 days (n = 65)
Study: 10223594
Drug: Immediate (IMM)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate (IMM) zidovudine therapy
Study: 10223594
Drug: Deferred (DEF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred (DEF) zidovudine therapy
Study: 7884546
Drug: Soycreme administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Soycreme administration
Study: 2203249
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) injections (0.1 mg/kg ideal body weight every other day)
Study: 2203249
Drug: Vehicle injections
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle injections (control)
Study: 2203249
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) injections
Study: 213374
Drug: Treatment overall
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment overall (including all types)
Study: 31228197
Drug: Theory-based social-cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theory-based social-cognitive intervention (4 weekly 1-hr face-to-face sessions)
Study: 21404089
Drug: Slow up-titration
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow up-titration of paroxetine (arm A)
Study: 21404089
Drug: Standard up-titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard up-titration of paroxetine (arm B)
Study: 7734295
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with cyclophosphamide, epirubicin and fluorouracil
Study: 2281427
Drug: Inhaled micronised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled micronised gentamicin powder (180 mg)
Study: 2281427
Drug: Nebulised gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised gentamicin solution (160 mg)
Study: 7027746
Drug: Metoprolol, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol, 100 mg b.i.d.
Study: 6219912
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g Meclocillin (single dose)
Study: 30401608
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (50,000 IU monthly for 24 months)
Study: 29614897
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplementation (ONS) plus dietary counselling (DC)
Study: 25238785
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of corticosteroids
Study: 25238785
Drug: Delayed antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed antibiotic prescription or no antibiotic prescription (control)
Study: 23185303
Drug: Control villages
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control villages (infants aged 2-30 months receiving Meningococcal C conjugate vaccine)
Study: 20098137
Drug: 0.1% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% ropivacaine (basal 12 ml/h, bolus 4 ml)
Study: 20098137
Drug: 0.4% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% ropivacaine (basal 3 ml/h, bolus 1 ml)
Study: 17363337
Drug: Alprazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (1 mg) in patients with panic disorder
Study: 17363337
Drug: Alprazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (1 mg) in healthy controls
Study: 16278615
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg of estradiol plus 2.0 mg of drospirenone (DRSP/E(2))
Study: 16278615
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg of estradiol alone (E(2) monotherapy)
Study: 9565058
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green staining of the anterior capsule
Study: 7622910
Drug: Escherichia coli
Normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escherichia coli infusion
Study: 2694741
Drug: Cefuroxim (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxim (1.5 g intravenous bolus at the beginning of and 12 hours after the operation)
Study: 2694741
Drug: Placebo (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous bolus at the beginning of and 12 hours after the operation)
Study: 375684
Drug: Mianserin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin (60 mg daily for four weeks)
Study: 28550081
Drug: Calcifediol (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcifediol (5000 IU 25-hydroxyvitamin D3), thrice weekly for 6 months
Study: 28550081
Drug: Calcitriol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (0.5 µg 1,25-dihydroxyvitamin D3), thrice weekly for 6 months
Study: 28550081
Drug: Placebo, thrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, thrice weekly for 6 months
Study: 28550081
Drug: Combined vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined vitamin D treatment (calcifediol and calcitriol)
Study: 28550081
Drug: Combined vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined vitamin D treatment
Study: 26560487
Drug: Transdermal 4-hydroxytamoxifen
Normalized name: 4-hydroxytamoxifen
DrugBank: Afimoxifene (DB04468)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 4-hydroxytamoxifen (4-OHT) gel applied daily to the axillary mammary gland for 6 weeks
Study: 26560487
Drug: Transdermal endoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal endoxifen gel applied daily to the axillary mammary gland for 6 weeks
Study: 26560487
Drug: Transdermal telapristone
Normalized name: Telapristone acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal telapristone acetate gel
Study: 26560487
Drug: Diclofenac patch
Normalized name: diclofenac Medicated Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac patch applied to the breast skin
Study: 26560487
Drug: Diclofenac patch
Normalized name: diclofenac Medicated Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac patch applied to the abdominal skin
Study: 21184267
Drug: Promotora-administered educational
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Promotora-administered educational intervention
Study: 10799369
Drug: DHA (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (4 g daily)
Study: 10799369
Drug: Both EPA
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both EPA and DHA (4 g daily)
Study: 1388336
Drug: Intravenous alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alfentanil bolus dose (30 micrograms/kg) followed by bolus doses of 10 micrograms/kg every 10 min
Study: 1388336
Drug: Intravenous alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alfentanil infusion (30 micrograms/kg induction dose over 1 min, followed by infusion at 1.0 micrograms.kg‐1.min‐1)
Study: 31367909
Drug: Moderate-dose exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose exercise (8 kcal/kg body weight/week)
Study: 31367909
Drug: High-dose exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose exercise (20 kcal/kg body weight/week)
Study: 31367909
Drug: Combined exercise
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined exercise groups (moderate and high-dose)
Study: 28832514
Drug: Avocado (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avocado (0.5 mg/day lutein)
Study: 28832514
Drug: Control (potato
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (potato or chickpeas, 0 mg/day lutein)
Study: 26655803
Drug: Epinephrine (0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (0.06 mcg.kg(1).min(‐1))
Study: 26655803
Drug: Levosimendan (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (0.2 mcg.kg(1).min(‐1))
Study: 17052490
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide 5% hydrogel/clindamycin 1% lotion + UVA irradiation
Study: 17052490
Drug: Fluticasone 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone 0.05% cream + UVA irradiation
Study: 12709680
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral folic acid per day
Study: 12709680
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg oral folic acid per day
Study: 12709680
Drug: Treated patients
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treated patients (5 mg and 15 mg)
Study: 8827136
Drug: Centrifuge subjects
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centrifuge subjects exposed to 15 s rapid onset (6 G.s‐1) + 5 Gz exposure while wearing a well‐fitting anti‐G suit (pressure inactivated)